Berger, Karoline Rhost, Sara Rafnsdóttir, Svanheiður Hughes, Éamon Magnusson, Ylva Ekholm, Maria Stål, Olle Rydén, Lisa Landberg, Göran
Published in
BMC Cancer
Background The growth factor progranulin has been implicated in numerous biological processes such as wound healing, inflammation and progressive tumorigenesis. Both progranulin and its receptor sortilin are known to be highly expressed in subgroups of breast cancer and have been associated with various clinical properties including tamoxifen resis...
Yang, Guan-Jun Zhu, Ming-Hui Lu, Xin-Jiang Liu, Yan-Jun Lu, Jian-Fei Leung, Chung-Hang Ma, Dik-Lung Chen, Jiong
Published in
Journal of Hematology & Oncology
Histone methylation is a key posttranslational modification of chromatin, and its dysregulation affects a wide array of nuclear activities including the maintenance of genome integrity, transcriptional regulation, and epigenetic inheritance. Variations in the pattern of histone methylation influence both physiological and pathological events. Lysin...
Schmid, Manuel Toepfer, Christopher N.
Published in
Biology Open
Summary: A discussion of the role and regulation of myosin super relaxation in biology, evolution, human disease, and cardiac therapeutics.
Miller, Kevin C. Chintakuntlawar, Ashish V.
Published in
Current Treatment Options in Oncology
With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or gene fusions to targeted therapies (e.g., selective RET inhibitors), delineating patients who are likely to r...
Perego, Gianluca Burgio, Valentina Nozza, Renata Longobardo, Giorgia Bernecich, Marco Luciani, Andrea Petrelli, Fausto
Published in
Medical Oncology
Biliary tract cancer is an uncommon cancer in developed countries. In localized stages, surgery is the cornerstone of treatment with curative purpose. Conversely in advanced stages, chemotherapy with platinum–gemcitabine combination is the standard of care. Biliary tract cancers are a biologically heterogeneous group of malignancies, which perhaps ...
Graham, Jeffrey Shah, Amishi Y Wells, J Connor McKay, Rana R Vaishampayan, Ulka Hansen, Aaron Donskov, Frede Bjarnason, Georg A Beuselinck, Benoit De Velasco, Guillermo
...
Published in
European urology oncology
Immuno-oncology (IO) therapies have changed the treatment standards of metastatic renal cell carcinoma (mRCC). However, the effectiveness of targeted therapy following discontinuation of IO therapy in real-world settings has not been well studied. To describe treatment sequence and assess clinical effectiveness of targeted therapy for mRCC patients...
Tamalunas, Alexander Schulz, Gerald B Rodler, Severin Apfelbeck, Maria Stief, Christian G Casuscelli, Jozefina
Published in
Der Urologe. Ausg. A
Mit jährlich etwa 30.000 Neuerkrankungen ist das Harnblasenkarzinom (BC) eines der häufigsten Karzinome in Deutschland, und die Inzidenz steigt mit dem Alter. Das Urothelkarzinom stellt die häufigste histologische Variante des BC in Mitteleuropa dar. Das nichtmuskelinvasive Karzinom der Harnblase kann endourologisch reseziert und über eine intraves...
Rosiello, Giuseppe Palumbo, Carlotta Knipper, Sophie Pecoraro, Angela Luzzago, Stefano St-Hilaire, Pierre-Antoine Tian, Zhe Capitanio, Umberto Montorsi, Francesco Shariat, Shahrokh F
...
Published in
World journal of urology
To compare survival outcomes of metastatic patients harbouring either papillary (pRCC) or clear-cell (ccRCC) renal cell carcinoma in overall population and according to treatment modality. Within the Surveillance, Epidemiology and End Results database (2006-2015), we identified 6800 patients (585 papillary and 6215 clear-cell) with metastatic RCC. ...
Raj, Sibi Khurana, Sartaj Choudhari, Ramesh Kesari, Kavindra Kumar Kamal, Mohammad Amjad Garg, Neha Ruokolainen, Janne Das, Bhudev C Kumar, Dhruv
Published in
Seminars in cancer biology
Nanotechnology has been the latest approach for diagnosis and treatment for cancer, which opens up a new alternative therapeutic drug delivery option to treat disease. Nanoparticles (NPs) display a broad role in cancer diagnosis and has various advantages over the other conventional chemotherapeutic drug delivery. NPs possess more specific and effi...
Rozenblit, Mariya Mun, Sophia Soulos, Pamela Adelson, Kerin Pusztai, Lajos Mougalian, Sarah
Published in
Breast Cancer Research
BackgroundThere is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patients with metastatic HR+ HER2− breast cancer previously treated with endocrine therapy (ET) or endocrine therapy...